Daily Stock List
Mainstream Entertainment, Inc. (MSEI)
Today we are highlighting Mainstream Entertainment, Inc. (MSEI), here at the QualityStocks Daily Newsletter.
As of January 25, 2013, Mainstream Entertainment, Inc. was acquired by First Power & Light, LLC, in a reverse merger transaction. Mainstream Entertainment, Inc. operates as an entertainment production company in the U.S. and Europe. The Company formerly went by the name Skreem Studios, Inc. They changed their name to Mainstream Entertainment, Inc. in August 2010. Founded in 2005, Mainstream Entertainment has their headquarters in Orlando, Florida. The Company's shares trade on the OTC Bulletin Board. First Power & Light has their corporate headquarters in Bridgeport, Pennsylvania.
On January 25, 2013, Mainstream Entertainment announced that the Company closed a Letter of Intent (LOI) with First Power and Light, LLC (First Power), a commercial, large residential, and Federal Government solar installation company. The terms of the closed LOI are that the shareholders of First Power are becoming the majority shareholders of Mainstream Entertainment.
As a solar installation company First Power and Light is looking to bring affordable and effective solar options to commercial, large residential and Federal Government customers across the United States. Their corporate goal is to provide industry-leading service and to save their customers money.
On February 8, 2013, Mainstream Entertainment announced that they intend to expand their business focus to include the sales and installation of commercial, federal and residential solar systems, change the address of their corporate headquarters, and appoint new Officers and Directors.
Mainstream Entertainment believes that the expansion of their business focus to include solar installation will be beneficial to shareholders because the U.S. is fast becoming a solar motivating force as domestic and global companies invest in new projects. A recent study by GTM Research and Solar Energy Industries Association (GTM Research) estimated that the U.S. solar market could grow eightfold to $8 billion by 2015. GTM Research is a market analysis company focusing on renewable energy industries.
Mainstream Entertainment, Inc. (MSEI), closed Tuesday's trading session at $1.29, up 4.03%, on 84,146 volume with 29 trades. The average volume for the last 60 days is 10,601 and the stock's 52-week low/high is $1.00/$1.20.
Odyssey Pictures Corp. (OPIX)
Today we are highlighting Odyssey Pictures Corp. (OPIX), here at the QualityStocks Daily Newsletter.
Headquartered in Plano, Texas, Odyssey Pictures Corp. engages in a complete spectrum of media and marketing related activities. These include content acquisition, multi-platform distribution and corporate finance. The Company is positioning themselves in the converging international sectors of new media, entertainment and strategic marketing. Odyssey Pictures provides diversified professional services to global media and entertainment markets. The Company was formerly known as Communications and Entertainment Corp. Founded in 1989, the Company lists on the OTC Markets' OTCQB.
The Company's lines of business include producer's representative services, corporate brand marketing, entertainment finance, and IPTV digital content delivery. Odyssey provides a broad suite of sales and marketing services to independent TV and film producers looking to gain a foothold in the global distribution and rights market. The services that Odyssey provides to them include International Sales & Licensing, Production, Film Tax Credits, Consulting, Marketing, and Completion Financing.
Odyssey Pictures involves in the development, production, marketing, and distribution of films and DVD's. In addition, the Company offers brand marketing; Website design and development; Internet broadcast development, specialized graphics and online business presentation; and hosting platform design services.
Odyssey Pictures' strategic partners include JL Media and Cat Studios. JL Media is a consulting enterprise that manages financial and operational interests for clients in media and production. Cat Studios is the foremost high-end 3-D animation and special effects house in the Central United States.
Odyssey Pictures' subsidiaries are Appaloosa and Filmzone. Appaloosa is an investment fund that concentrates on short-term financing opportunities in new media markets. Filmzone engages in rights management solutions for entertainment related properties.
In May 2012, Odyssey Pictures announced a sales and distribution partnership with IndiePIX, a leading online film distribution service for the independent film community. Odyssey's Producer's Representative service will have the exclusive foreign market sales rights for 25 hand picked titles from the IndiePIX library. The agreement also gives Odyssey the right of first refusal for North American rights. Odyssey will market and promote the new titles through traditional sales and distribution outlets and via digital distribution platforms.
Odyssey Pictures Corp. (OPIX), closed Tuesday's trading session at $0.035, up 483.33%, on 18,002,447 volume with 1,064 trades. The average volume for the last 60 days is 9,835 and the stock's 52-week low/high is $0.0043/$0.061.
Southern ITS International, Inc. (SITS)
Penny Stock Rumble reported today on Southern ITS International, Inc. (SITS), PennyAuthority.com, KO PENNY STOCKS, Eastwind Research, ExclusiveStockAlerts, Pumps and Dumps, AwesomePennyPicks, GoldmanStockReport, SmallMovesBigGains, Penny Stock Buyers, Momentum Hunter, ElitePennyStocks, Penny Lane Reports, Penny King, PennyTrader, and OtcWizard also reported this month, and we highlight the Company, here at the QualityStocks Daily Newsletter.
Southern ITS International, Inc.'s focus is providing total systems integration projects through maintaining cost effectiveness while providing the highest end voice, data, surveillance, audio/visual and fire detection available. The Company is providing a digital video recording (DVR) solution and integrating their technological solutions with other existing systems. This results in a significant capital savings for the Company's clients. Southern ITS International is based in Las Vegas, Nevada.
The Company's operations consist of providing turnkey integration of electronic security systems for diverse types of industries. These include transportation, gaming and other secure operations in government and private sectors. The integration includes surveillance, access control, network infrastructure, and data com, fire, and burglar alarm systems. Southern ITS' mission is to provide a complete integration of the different electronic security systems with the computer networks that they are dependent upon and ensuring that the systems will remain secure from potential cyber attack.
Yesterday, Southern ITS International announced that they entered into final negotiations with Gephart Electric Co. for a Datacom infrastructure contract including a network system in the state of Maryland. Gephart Electric has been a leader in the industry for more than 30 years.
In addition, yesterday, Southern ITS International announced that they completed the final phase of restructuring by changing their trading symbol to SITS and affecting a forward 2-for-1 split of their common stock. Additionally, their intention is to pursue their plan to become a fully reporting Company and potentially being listed on the OTC Markets' OTCQB. The Company currently lists on the OTC Pink Current Information.
Mr. Jason Bell, CEO of Southern ITS International, noted, "The Company is now positioned to aggressively move forward with implementation of our exciting business plan. The positive changes that we have completed will allow us to expand our presence in our business sector. The Company is in negotiations to increase our business on several fronts. It is my belief that we will be in a position to announce positive developments in the near future."
Southern ITS International, Inc. (SITS), closed Tuesday's trading session at $0.0074, down 12.94%, on 46,169,288 volume with 514 trades. The average volume for the last 60 days is 1,470,098 and the stock's 52-week low/high is $0.001/$2.7273.
Cline Mining Corp. (CMK.TO)
We are highlighting Cline Mining Corp. (CMK.TO), here at the QualityStocks Daily Newsletter.
Cline Mining Corp. has metallurgical coal property interests in British Columbia and in Colorado with NI 43-101 independent Technical Reports. The Company focuses on the exploration and development of metallurgical steel making coals in Canada and the U.S. They also focus on their iron ore property in Madagascar and their Cline Lake gold property in northern Ontario. The Company is a growth-oriented mine finder, developer and operator with an experienced management team.
Cline Mining has their headquarters in Toronto, Ontario. The Company lists on the Toronto Stock Exchange. Cline is developing their Lodgepole metallurgical coalmine projects in British Columbia. Concerning the Lodegpole, Sage Creek, and Cabin Creek coal properties, effective as of February 9, 2010, British Columbia Regulation 41/2010 has created a new mineral and coal reserve that covers all lands within the Flathead River watershed, imposing a moratorium on the acquisition or issuance of mineral, placer and coal tenure within the reserved area.
Additionally, Cline has completed an extensive diamond drill program on the Cline Lake Gold Mine Property located in Jacobson Township in the Wawa gold camp in Northern Ontario. The results were presented in a National Instrument 43-101 report prepared by independent consultant Dr. D. McBride PEng in December 2009. The NI 43-101 report identified seven significant new gold zones and areas of potential for future exploration work. The Company is also engaging in additional iron ore mineral exploration on extensions and step-out areas at their Bekisopa, Madagascar iron ore properties.
Moreover, Cline is engaged in the development of their New Elk metallurgical and thermal coalmine property in Trinidad, Colorado. The New Elk coal mine, located in southern Colorado, has NI 43-101 compliant Measured and Indicated Resources of 618.9 million tons of low sulfur, high-volatile, B bituminous coal. This can be marketed as a high-ash metallurgical grade coal, a PCI coal, or a thermal coal. The Company owns 100 percent of the New Elk Coal Mine.
Recently, Cline Mining announced that they retained GMP Securities L.P. as their exclusive financial advisor. GMP's mandate includes assisting Cline in exploring and evaluating strategic alternatives to the recapitalization plan with Marret Asset Management, Inc. previously described in the Company's press release dated December 27, 2012. Under the terms of an agreement with Marret, on behalf of certain bondholders of the Company, the Marret Plan will undergo implementation unless, by February 28, 2013, Cline has received a non-binding letter of intent (LOI) for a transaction that meets specified criteria and, among other things, such transaction closes by April 30, 2013.
Cline Mining Corp. (CMK.TO), closed Tuesday's trading session at $0.145, up 52.63%, on 6,829,246 volume. The stock's 52-week low/high is $0.05/$2.07.
Orex Minerals, Inc. (REX.V)
Today we are highlighting Orex Minerals, Inc. (REX.V), here at the QualityStocks Daily Newsletter.
Orex Minerals, Inc. is a junior exploration company whose shares trade on the TSX Venture Exchange. The Company has two very distinctive precious metals plays in their portfolio. One is the Barsele Gold Project (Sweden) and the other is the Coneto Silver-Gold Project (Durango, Mexico). Orex Minerals mainly explores for gold and silver metals. Incorporated in 1996, the Company has their corporate headquarters in Vancouver, British Columbia.
Their advanced-stage Barsele Gold Project is near Storuman, Västerbottens Län, approximately 600 km north of Stockholm, Sweden. Sweden is one of Europe's leading producers of metals with a long and successful history of mining. Barsele has an NI 43-101 Compliant Resource Estimate (using 0.6 g/t Au cut-off) that defines on the Central-Avan-Skiråsen gold zones an Indicated Resource of 14.1 million tonnes grading 1.21 gold grams per tonne (g/t) or 547,000 contained ounces of gold.
Furthermore, the study has estimated additional Inferred Resources of 20.2 million tonnes grading 0.97 gold grams per tonne (g/t) or 627,000 contained ounces of gold. A number of major gold deposits are located nearby. These include Bjorkdal (Elgin Mining), Faboliden (Lappland Gold) and Svartliden (Dragon Mining).
The Company's Coneto Silver-Gold Project is contiguous to the village of Coneto de Comonfort, centrally positioned within the "Mexican Silver Trend", approximately 100 km north of the city of Durango, Mexico. In February 2012, Orex Minerals signed an Association Agreement with Fresnillo PLC to explore the Coneto property with joint management of the drilling program.
Orex has 100 percent ownership of 15,700 ha of mineral concessions at Coneto. Coneto has been a mining camp since the days of the Conquistadores. More than 40 veins of silver and gold have been documented in the Coneto mining camp, some more than 20 m wide and extending more than a km in length. Very little diamond drilling has occurred on this property.
Recently, Orex Minerals announced the results of the second batch of holes from the 12,000 meters Phase-II diamond-drilling program on the Coneto Gold-Silver Project. A technical committee, with representation of Orex and their project partner Fresnillo PLC (FRES.L), is managing this Phase-II program. Hole BCO-11 yielded a high-grade Santo Niño vein intercept of core length of 3.30 meters (true width 2.70 meters) grading gold 4.34 g/t and silver 612 g/t, for a gold-equivalent of 16.00 g/t, or silver-equivalent of 840 g/t.
Orex Minerals, Inc. (REX.V), closed Tuesday's trading session at $0.52, down 7.14%, on 5,551 volume. The stock's 52-week low/high is $0.28/$0.85.
Zhone Technologies, Inc. (ZHNE)
SmallCap Network reported today on Zhone Technologies, Inc. (ZHNE), Stock Stars, MonsterStocksPicks, SmarTrend Newsletters, Greenbackers, PennyInvest, MadPennyStocks, StockEgg, BullRally, PennyStockVille, StockRich, HotOTC, CoolPennyStocks did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.
Listed on the NASDAQ Capital Market, Zhone Technologies, Inc. is an international leader in all IP multi-service access solutions. The Company's commitment is to building the fastest and highest quality All IP Multi-Service solution for their clientele. Zhone Technologies serves over 750 of the world's most innovative network operators. The Company is a leader in Fiber to the x (FTTx) network access solutions. Zhone Technologies has their headquarters in Oakland, California.
The Company has large-scale worldwide deployments of their high-capacity FTTx multi-service systems including the MXK, MALC and zNID ONTs. The design of these is to provide high performance and cost-effective solutions for the operator's bandwidth requirements. Zhone Technologies' equipment provides carriers FTTx solution options for strategically introducing Active Ethernet and GPON while ensuring a migration path to emerging 10G access technologies.
Last week, the Company announced that through a partnership with reseller Digistar, Brazilian company Klisa Telecom has deployed the Zhone MXK solution to support advanced broadband services in the city of Montes Claros, Brazil. The company also selected the platform for 10 additional cities in the state of Minas Gerais, Brazil.
Klisa Telecom plans to offer high-speed voice and data services to their customers using the MxK 819 with a mix of GPON, ADSL+POTS and VDSL2+POTS combo cards for FTTx services. Klisa Telecom selected Zhone's solutions due to its scalability and ease of deployment, along with Zhone's reputation for high quality customer service.
Zhone Technologies' MXK platform is a fully redundant, carrier-grade all-IP platform. It is the industry's first terabit access concentrator. It features industry-leading density, scalability and switching capacity. The MXK provides non-blocking capacity of up to 3,600 100 Mbps GPON subscribers or 360 1G Active Ethernet subscribers.
Additionally, last week, Zhone Technologies reported that the Company continues to gain momentum for the worldwide deployment of their industry-leading MXK™ multi-service access node (MSAN), garnering substantial growth for their Gigabit Passive Optical Network (GPON), Active Ethernet (AE) and Very-High-Bit-Rate Digital Subscriber Line (VDSL2) connectivity. In Q4 2012, they shipped over 400 MXKs, expanding the total number of MXK platform deployments to over 4,400 units. To date, Zhone has shipped more than 3 million of their GPON Ports internationally and generated a total subscriber capacity of more than 30 million.
Zhone Technologies, Inc. (ZHNE), closed Tuesday's trading session at $0.90, up 13.22%, on 560,853 volume with 830 trades. The average volume for the last 60 days is 72,036 and the stock's 52-week low/high is $0.4022/$1.4099.
American Power Group Corp. (APGI)
We are reporting on American Power Group Corp. (APGI), here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, American Power Group Corp. is a designer and producer of proven alternative fuel solutions. Founded in 1992, the Company formerly went by the name GreenMan Technologies, Inc. They changed their name to American Power Group Corp. in July 2012. American Power Group has their headquarters in Lynnfield, Massachusetts.
The Company's solutions are for stationary power generators, backup power systems and commercial transportation. Their alternative energy subsidiary, American Power Group, Inc., provides a cost-effective patented Turbocharged Natural Gas™ conversion technology for aftermarket vehicular, stationary and off-road mobile diesel engines. American Power, via the science of combustion, creates dual fuel systems. These proprietary solutions supply a blend of economical natural gas alternatives and diesel specifically harmonized to the unique specifications of commercial diesel engines. The Company's dual fuel systems use as much as 50 percent low cost natural or methane gas content.
American Power Group's dual fuel technology is a non-invasive energy enhancement system. It converts existing diesel engines into more efficient and environmentally friendly engines that have the flexibility to run on diesel fuel and liquefied natural gas; diesel fuel and compressed natural gas; diesel fuel and pipeline or wellhead gas; and diesel fuel and bio-methane. It has the flexibility to return to 100 percent diesel fuel operation at any time.
Methane gas is metered into a diesel engine's air intake, before the turbocharger, by the air filter. As the enriched air/gas mixture increases the engine's power, the diesel's own governor senses the power increase and backs off on diesel flow. The Company's system maintains a balance of gas-to-diesel ratios, (approximately 80-50 percent natural gas to 20-50 percent diesel fuel) keeping the proper BTU energy within the engine across its power curve.
The proprietary technology seamlessly displaces up to 80 percent of the normal diesel fuel consumption with the average displacement ranging from 40 percent to 65 percent. The maintenance of the energized fuel balance is with a proprietary read-only electronic controller system ensuring the engines operate at original equipment manufacturers' (OEMs) specified temperatures and pressures. Installation on a broad spectrum of engine models and end-market applications require no engine modifications.
In January, the Company announced that their subsidiary, American Power Group (APG) received purchase orders totaling $1.5 million from Cudd Energy Services to upgrade and convert diesel pumps used for hydraulic fracturing to APG's Turbocharged Natural Gas™ Dual Fuel System. APG will provide full turnkey installation including engineering services under an EPA Test Exemption while completing the EPA Memo 1A Testing and Compliance process. The Company expects the completion of the installations to be during the next two calendar quarters in conjunction with the scheduled completion of the Memo 1A Testing.
Recently, American Power Group announced that they would host a conference call on Wednesday; February 13, 2013 at 10:00 AM Eastern in which they will discuss the results for the three months ended December 31, 2012.
American Power Group Corp. (APGI), closed Tuesday's trading session at $0.70, down 5.41%, on 13,840 volume with 10 trades. The average volume for the last 60 days is 64,421 and the stock's 52-week low/high is $0.38/$0.89.
USA Technologies, Inc. (USATZ)
Wall Street Resources reported recently on USA Technologies, Inc. (USATZ), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
USA Technologies, Inc., via their ePort® line of products and services, provides wireless networking, cashless transactions, asset monitoring and other value-added services mainly to the small ticket, unattended retail markets. The Company has developed substantial expertise and proprietary software. They have been granted 84 patents. USA Technologies is a leader of wireless, cashless payment and M2M (Machine-to-Machine) telemetry solutions. Incorporated in Pennsylvania in 1992, the Company is based in Malvern, Pennsylvania. USA Technologies lists on the NASDAQ Global Market.
USA Technologies' extensive line of cashless acceptance technology includes their NFC-ready ePort G8, ePort Mobile™ for customers in transit, and QuickConnect™, an API Web service for developers. The Company's ePort technology can undergo installation and/or embedding into everyday devices such as vending machines, kiosks, as well as their eSuds™ technology for commercial washers and dryers. The Company has agreements with Verizon, Visa, Elavon and leading customers such as Compass, Crane, AMI Entertainment and others.
ePort Connect® is the Company's associated network service, a PCI compliant, complete family of cashless payment and telemetry services designed specifically for the unique needs of the small ticket, unattended market. ePort Connect includes wireless connectivity that facilitates electronic payments options and telemetry and M2M services. This includes the ability to remotely monitor, control and report on the results of distributed assets using the Company's electronic payment solutions. ePort Connect® enables self-service terminals to accept credit, debit, contactless cards and other cashless forms of payment and it handles all elements of transaction processing.
USA Technologies also provides energy management products through their EnergyMiser line. These include VendingMiser® and CoolerMiser™, which reduce energy consumption in vending machines and coolers.
Last week, USA Technologies announced a new agreement with Ice House America™. The agreement covers the use of the Company's ePort® and ePort Connect® cashless payment and telemetry services for Ice House America's units located throughout the United States and establishes USA Technologies as a preferred partner. Ice House America™ is a pioneer in automated ice vending technology.
USA Technologies, Inc. (USATZ), closed Tuesday's trading session at $1.30, up 8.32%, on 860 volume with 7 trades. The average volume for the last 60 days is 12,492 and the stock's 52-week low/high is $0.051/$1.55.
Cardium Therapeutics, Inc. (CXM)
The QualityStocks Daily Newsletter would like to spotlight Cardium Therapeutics, Inc. (CXM). Today, Cardium Therapeutics, Inc. closed trading at $0.19, up 1.33%, on 421,837 volume with 239 trades. The stock’s average daily volume over the past 60 days is 175,865, and its 52-week low/high is $0.17/$0.31.
Cardium Therapeutics, Inc. was pleased to announce reception today of the American Podiatric Medical Association's (APMA) coveted Seal of Approval for the company's innovative ExcellagenŽ advanced wound care product, thanks to the massive contributions to better foot health and mobility the product represents. Given the position of the APMA as the leading professional organization for podiatrists in the country, this announcement is a powerful endorsement for the company's FDA-cleared syringe-based, professional-use, and pharmaceutically-formulated 2.6% fibrillar Type I bovine collagen gel. Excellagen was designed from the start to provide a new paradigm in the treatment of neuropathic and diabetic foot ulcers, as well as pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds.
Cardium Therapeutics, Inc. (CXM) is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways to commercialization, partnering, and other economic monetizations, Cardium's current portfolio includes the Tissue Repair Company, Cardium Biologics, and the company's in-house MedPodium Health Sciences healthy lifestyle product platform.
The company's lead commercial product Excellagen® topical gel for wound care management recently received FDA clearance for marketing and sale in the United States. In addition to plans to advance the product's commercialization in the U.S. and internationally via strategic partnerships, the company plans to develop new product extensions for additional wound healing applications and is working towards securing approval for marketing and sale in South Korea and through the CE Mark application process in the European Union.
Generx®, Cardium's lead clinical development product candidate, is a DNA-based angiogenic biologic designed to treat patients with myocardial ischemia due to coronary artery disease. Cardium recently initiated its Generx Phase 3 / registration study in Russia. Consistent with its capital-efficient business model, Cardium is also actively evaluating new technologies and business opportunities. The company utilizes its team's skills in late-stage product development to bridge the critical gap between promising new technologies and product opportunities that are ready for commercialization.
Cardium is dedicated to building on its core products and product candidates to continually create new opportunities for greater success. Leveraging the advantages of its capital-efficient, asset-based business strategy, the company provides a diversified and more balanced portfolio of risk/return opportunities with the chief objective of providing long-term shareholder value. Disclaimer
Cardium Therapeutics, Inc. Company Blog
Cardium Therapeutics, Inc. News:
Cardium's ExcellagenŽ Awarded American Podiatric Medical Association Seal of Approval, Company Also Announces Addition of a Regional Distributor for Excellagen
Cardium Announces Presentation at The 2013 Cell & Gene Therapy Forum
Cardium To Present At Biotech Showcase 2013 Investment Conference And Report On New Cardium Initiatives
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.381, off by 2.31%, on 128,973 volume with 56 trades. The stock’s average daily volume over the past 60 days is 212,482, and its 52-week low/high is $0.161/$0.65.
International Stem Cell Corp. announced positive results today from their efficacy and safety of the human parthenogenetic stem cell (hpSC) derived hepatocyte-like cells (HLC) using a well-established animal model for Criggler-Najjar syndrome type 1 (CN1), a rare inherited metabolic disorder of the liver. These results establish the necessary ground work for an IND with the FDA, and ISCO is looking forward to taking the technology into Phase I clinical trials, invigorated by the obvious potential of implanted HLC which caused a significant drop and long-term stabilization effect of this neurologically dangerous syndrome in the study.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.
A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.
In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Demonstrates Positive Animal Efficacy Results in Metabolic Liver Disease Program
International Stem Cell Corporation Announces Positive Results From In Vivo Animal Study of Parkinson's Disease
International Stem Cell Corporation Announces Positive Animal Efficacy Results in Liver Disease Program
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.69, up 4.55%, on 12,066 volume with 10 trades. The stock’s average daily volume over the past 60 days is 1,991, and its 52-week low/high is $0.06/$3.10.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen's Collaborators Identify Definitive Precursor for Adult Blood and the Immune System
Vistagen Therapeutics Successfully Completes Final Phase 1 Safety Study of AV-101
VistaGen Therapeutics to Present at Noble Financial Capital Markets Ninth Annual Equity Conference
Rainbow Coral Corp. (RBCC)
The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.40, up 2.56%, on 101,240 volume with 53 trades. The stock’s average daily volume over the past 60 days is 92,899, and its 52-week low/high is $0.27/$2.67.
Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.
Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.
The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.
The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer
Rainbow Coral Corp. Company Blog
Rainbow Coral Corp. News:
RBCC: n3D Technology Could Lead to Lab-Grown Implantable Organs
RBCC Partner N3D Could Revolutionize Toxicity Testing
RBCC Visits Texas Genome-Mapping Target
Today before the opening bell, Cardium Therapeutics announced that the American Podiatric Medical Association (APMA) has granted its prestigious Seal of Approval to Excellagen®, Cardium’s advanced, FDA-cleared wound care product, for improving foot health and mobility. Excellagen is a syringe-based, professional-use, pharmaceutically formulated 2.6% fibrillar Type I bovine collagen gel that functions to activate the wound healing process and accelerate the growth of granulation tissue. Excellagen can be used to treat neuropathic and diabetic foot ulcers, pressure ulcers, venous ulcers, surgical wounds, and other dermal wounds.
APMA, the nation’s leading professional organization for podiatrists, has 53 state component locations across the United States and its territories, with a membership of more than 12,000 licensed podiatrists. Excellagen passed an extensive scientific review by a panel of APMA members and was recommended by a committee of Doctors of Podiatric Medicine (DPMs) to the APMA Board of Trustees. For more information, visit www.apma.org.
“Excellagen has proven to be an important treatment for wound care and has been thoroughly reviewed and found to be beneficial to foot health. For this reason, it has been granted APMA’s Seal of Approval,” stated Joseph M. Caporusso, DPM, President of the APMA.
“We are pleased to receive the highly regarded APMA Seal of Approval for our Excellagen advanced wound care product. The APMA assists physicians and their patients to make informed decisions about their foot health, and we are proud that Excellagen has completed the thorough review process and met the APMA’s standards and requirements for its Seal of Approval. Excellagen was also selected as a 2012 Top 10 Innovations in Podiatry by Podiatry Today publication and we appreciate the industry recognition that Excellagen is now receiving,” commented Christopher J. Reinhard, Cardium’s Chairman and CEO.
In other news today, the company also announced that it has retained an additional independent distributor group consisting of ten sales representatives to market, sell, and distribute Excellagen to podiatric and orthopedic physicians, plastic surgeons, hospitals, and surgical centers located in North Carolina and South Carolina. The distributor’s customer base specializes in the treatment of diabetic foot ulcers and surgical wounds, including post-Mohs cancer surgery and trauma wounds. On January 3, 2013, Cardium announced a distribution agreement with Academy Medical, LLC to market, sell, and distribute Excellagen to U.S. government medical providers, including the Veterans Administration (VA) healthcare system and military hospitals. Academy Medical has a growing customer base of over 35 VA and military hospitals within the U.S.
Reinhard concluded, “The addition of our new regional distributor and our recent agreement with Academy Medical will expand our distribution capabilities for Excellagen as we advance forward with our planned U.S. strategic partnering activities. Consistent with our long-term business strategy, we do not plan to establish an internal sales force for Excellagen and continue to focus on broadening representation, marketing and sales, and co-promotional arrangements targeting four U.S. vertical wound healing market channels: (1) podiatry, (2) wound care centers, hospitals and long-term care facilities, (3) government medical service providers; and (4) dermatology. We are also advancing international registrations for Excellagen, including CE Mark registration, which is expected in first quarter 2013, to enable marketing and sales in the European Union and in other international markets where the CE Mark is considered an important commercial recognition of quality.”
For more information on Cardium and its advanced wound care product, visit www.cardiumthx.com
International Stem Cell, the biotech developer of a powerful human parthenogenetic stem cell (hpSC) technology platform which yields pluripotent cells from unfertilized eggs that can be immune-matched to millions of humans irrespective of sex and racial genetic makeup, reported conclusions from their efficacy/safety study of hpSC-derived hepatocyte-like cells (HLCs) in congenital liver disorder associated with bilirubin metabolism, using a firmly established animal model.
The potential for this solution in Criggler-Najjar syndrome type 1 (CN1), a dangerous inherited metabolic disorder of the liver characterized by abnormal buildup of the toxin bilirubin due to the absence of the enzyme UGT1A1, is immense. CN1 often results in severe neurological problems and can even lead to irreversible brain and nervous system damage if it goes untreated. Luckily the company has previously reported on how HLCs engraft in Gunn rat livers, offering a solid animal model benchmark where the animal’s natural lack of the key enzyme grants exceptional clarity regarding therapeutic HLC dosing results.
As expected, the newest data from this pre-clinical study roundly confirms the bilirubin-level stabilization effects of implanting HLC in the rodents, as well as showing a serious initial punch after implantation that decreased bilirubin concentration in the blood serum considerably. Similarly, the safety metrics are essentially validated and one can look at the 16-week run without any safety signals going off, as well as the sustained offsetting of bilirubin levels up to the conclusion at the 19-week mark as sound indicators of the safety of this implanted HLC solution. In fact, overall liver morphology across the board in the treatment group showed no signs of cell rejection, inflammation, or tumor production, and the tissues were apparently completely undamaged.
VP of R&D for ISCO, Dr. Ruslan Semechkin, called this latest study a source of important evidence for the company’s HLC product in CN1 and conveyed everyone’s excitement at ISCO over now being primed to hammer out IND (investigational new drug) application requirements with the FDA in anticipation of Phase I clinical trials. The strength of the animal model really shines here and ISCO looks like they have another big emerging therapeutic winner on their hands, stemming once again from a powerful core biotech platform which the company has developed in therapeutic and regenerative hpSC applications. When taking a look at the company’s broader therapeutic programs based on this technology, it is easy to see the potential impact in diseases of the eye, nervous system, and liver. Cell therapy has proven clinically effective in all of those cases but until now the lack of safe, immune-matched human cells has been sorely lacking, making such therapy a mere pipedream.
This is a major breakthrough compared to extant Allogenic hepatocyte transplantation (HT), which has been used in CN1 and other metabolic liver diseases. The shortage of mature functioning cells and limited repopulation potential for grafted adult cells has hampered the effectiveness of HT sharply. There are several distinct advantages to the HLC approach besides hurdling this obvious cell shortage issue and the most striking one is the impressive long-term repopulation capacity of these HLCs, which stimulate a tenacious persistence in metabolic activity not seen in standard HT transplants. What’s more, because the HLC methodology allows for in vitro production and expansion, appropriate quantities can be derived and administered well before the onset of bilirubin-associated damage to the brain or nervous system ever occurs, with the HLC’s shoveling out enough enzyme to help the liver properly metabolize the toxin.
For more information on International Stem Cell Corp., visit www.InternationalStemCell.com
Bergamo Acquisition has developed a unique funding process, allowing the company to pursue its strategy of building a diverse acquisition portfolio of growth companies. The necessary due diligence required to ensure and secure the large volumes of money involved in the process is, of course, of utmost importance.
The most critical aspect in all this is the formal transfer and confirmation of investment funds. Fortunately, the company and its subsidiaries has at its service the world’s third largest publicly held bank, HSBC, to ensure that all of the proper steps are followed, and that the money is successfully transferred.
• A detailed compiled financial statement on Bergamo is prepared by a certified public accounting firm.
• A formal Bond Power / Deed of Assignment and Power of Attorney is assigned to provide the necessary parties with the authority to act on the behalf of the major investors in the transfer of the specified funds, including associated certifications.
• An attorney permitted to practice before the Securities and Exchange Commission examines all associated Bergamo corporate records and other documents related to their disclosures, and presents a formal statement verifying the authenticity and accuracy of the information.
• A formal investment agreement is signed between Bergamo European subsidiary and the authorized investor representatives, and detailed in formal press releases.
• Finally, the funding is verified through the formal HSBC bank statements, with all associated transaction documents available through the company website, filings, and in conjunction with associated press releases.
Documentation has been made available by Bergamo, verifying the funding of its European subsidiary consistent with its non-disclosure and non-circumvent agreements.
For more information, visit the Bergamo website at www.BergamoCorp.com
After a long time on the bench, the housing market is back. Nationally, housing prices have seen the biggest gains in seven years, with some states seeing jumps exceeding 9%. Arizona, one of the states hardest hit by the real estate crash, has seen an annual housing price increase of over 16%. A recent report listed all 50 states as now showing improving markets. Correspondingly, although there are still many cash sales, and in spite of the stricter lending requirements now in place, there were a reported 8.6 million mortgage originations in 2012, the highest level since 2007. And, for 2013, existing home sales are expected to rise by another 9%.
In addition, as the job outlook improves, the number of people with sub-prime credit scores is shrinking, strengthening the market for new houses. Until recently, only people who were relatively well off could get through the tighter credit and income filters to buy a home, and these people purchased bigger homes, keeping the price of builders fairly high. Now, with more people able to measure up, home sales of all types should benefit.
It’s an environment well suited for Loans4Less.com, a growing online residential mortgage broker based in California. The company is focused on so-called “A” paper loans, requiring good credit, good income, and a good down payment. As a leader in online brokerage, Loans4Less has an expansion strategy that isn’t constrained by the costs and lead time of brick-and-mortar operations.
For more information, visit www.Loans4Less.com
Today's Top 3
The QualityStocks Public Company Sponsor News